Elpiscience, a Shanghai-based biopharmaceutical company has completed a $100 million Series B round of funding led by specialist healthcare GP Hyfinity Investments.
Tencent Holdings, GTJA Investment Group, Dyee Capital, Oriza Holdings, Ming Bioventures, WisdoMont Asset Management, and Parkway Global also joined the round. Existing investors Lilly Asia Ventures (LAV),...
Warburg Pincus will sell an approximately 5.5% interest in Hong Kong-listed IVF services provider Jinxin Fertility for about HK$1.5 billion ($194 million) through a share placement.
CLSA, the international arm of China-based brokerage CITIC Securities, has launched a strategy to offer high net worth clients investment opportunities in late-stage private companies in Asia.
DCM Ventures has raised $880 million across two funds that will continue its early-stage technology strategy, with 70% of the capital earmarked for deployment in China.
Having previously focused on offshore IPOs, China managers with US dollar funds are now considering the Star Market. But going onshore means more regulation as well as high valuations